title: Sustained response to combination therapy in a patient with chronic hepatitis C and thrombocytopenia secondary to alpha-interferon.
abstract: Recent data suggest that hepatitis C viral (HCV) infection may induce a significant autoimmune reaction to platelets, but the mechanism is unknown. Many patients with chronic hepatitis C, in fact, have high levels of platelet-associated immunoglobulin G (PAIgG) and HCV-RNA is present in the platelets of 100% of those patients with thrombocytopenia and high PAIgG levels. Hepatitis C virus infection has been associated with the development of thrombocytopenic purpura, sometimes triggered during interferon (IFN) therapy. In such cases, the treatment of the underlying disease is a difficult problem to solve. We report the case of a patient with chronic hepatitis C, who developed life-threatening thrombocytopenic purpura after a prolonged course of IFN-alpha2b over a 4-year period. Treatment with anti-immunoglobulin gammaglobulin (Polyglobin; Química Farmaceutica Bayer, Barcelona, Spain) had a transient effect on the platelet count, but prolonged therapy with prednisone was necessary for definitive relief of the haematological complication. Two years later, the patient was treated with combined therapy, including ribavirin (1200 mg/day) and IFN-alpha2b (5 mU, t.i.w.) for 12 months. This therapy induced a sustained response, both biochemical and virological, without haematological complications. This observation suggests that ribavirin may be of benefit in the treatment of immune-mediated thrombocytopenia in patients with chronic hepatitis C, preventing the harmful effect of IFN-alpha but also allowing both drugs to be combined so as to increase the probability of sustained remission of the liver disease.
authors.affiliation: Division of Gastroenterology-Liver Unit, Hospital Universitario Virgen Macarena, Sevilla, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Jiménez-Sáenz
authors.forename: M
authors.initials: M
authors.lastname: Rojas
authors.forename: A
authors.initials: A
authors.lastname: Piñar
authors.forename: E
authors.initials: E
authors.lastname: Salas
authors.forename: J
authors.initials: J
authors.lastname: Rebollo
authors.forename: I
authors.initials: I
authors.lastname: Carmona
authors.forename: J M
authors.initials: JM
authors.lastname: Herrerías-Esteban
authors.forename: J M
authors.initials: JM
authors.lastname: Herrerías-Gutiérrez
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D019698:Hepatitis C, Chronic / Q000628:therapy*; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000188:drug therapy
chemical_list: D000998:Antiviral Agents; D007074:Immunoglobulin G; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012254:Ribavirin; D011241:Prednisone